732 related articles for article (PubMed ID: 29623600)
21. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.
Liu JW; Zuo XL; Wang S
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3655-73. PubMed ID: 26502856
[TBL] [Abstract][Full Text] [Related]
23. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
24. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].
Zhang PR; Ma XL; Guo L; Lu RQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):885-890. PubMed ID: 37357208
[No Abstract] [Full Text] [Related]
25. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
26. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
27. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.
Yang JD; Dai J; Singal AG; Gopal P; Addissie BD; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1085-1092. PubMed ID: 28258053
[No Abstract] [Full Text] [Related]
28. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
29. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients.
Shaheen NMH; Zayed N; Riad NM; Tamim HH; Shahin RMH; Labib DA; ELsheikh SM; Moneim RA; Yosry A; Khalifa RH
Virus Res; 2018 Aug; 255():77-84. PubMed ID: 30003924
[TBL] [Abstract][Full Text] [Related]
30. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
Chang TS; Wu YC; Tung SY; Wei KL; Hsieh YY; Huang HC; Chen WM; Shen CH; Lu CH; Wu CS; Tsai YH; Huang YH
Am J Gastroenterol; 2015 Jun; 110(6):836-44; quiz 845. PubMed ID: 25869392
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis.
Worland T; Harrison B; Delmenico L; Dowling D
J Gastrointest Cancer; 2018 Dec; 49(4):476-480. PubMed ID: 28920172
[TBL] [Abstract][Full Text] [Related]
32. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
33. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein.
Paul SB; Gulati MS; Sreenivas V; Madan K; Gupta AK; Mukhopadhyay S; Acharya SK
Oncology; 2007; 72 Suppl 1():117-23. PubMed ID: 18087192
[TBL] [Abstract][Full Text] [Related]
34. [The value of serum glypican-3 level in aided diagnosis of patients with primary hepatocellular carcinoma].
Tang XY; Wang YC; Lu RQ; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):998-1002. PubMed ID: 32907292
[No Abstract] [Full Text] [Related]
35. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients.
Ibrahim GH; Mahmoud MA; Aly NM
Mol Biol Rep; 2013 Dec; 40(12):7069-75. PubMed ID: 24186850
[TBL] [Abstract][Full Text] [Related]
37. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma.
Zhang Q; Xiao Q; Lin Z; Ying X; Li Z; Lin JM
Clin Biochem; 2010 Aug; 43(12):1003-8. PubMed ID: 20444424
[TBL] [Abstract][Full Text] [Related]
38. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature.
Yang SL; Fang X; Huang ZZ; Liu XJ; Xiong ZF; Liu P; Yao HY; Li CH
Dis Markers; 2014; 2014():127831. PubMed ID: 25378766
[TBL] [Abstract][Full Text] [Related]
39. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
[TBL] [Abstract][Full Text] [Related]
40. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.
Hagag NA; Ali YBM; Elsharawy AA; Talaat RM
J Gastrointest Cancer; 2020 Mar; 51(1):234-241. PubMed ID: 31028536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
